Neutrophil proteolytic activation cascades: A possible mechanistic link between chronic periodontitis and coronary heart disease

Innate Immunity

Volumn 22, Issue 1, 2016, Pages 85-99

  Alfakry, Hatem ^a   Malle, Ernst ^b   Koyani, Chintan N ^b   Pussinen, Pirkko J ^a   Sorsa, Timo ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Aggregatibacter actinomycetemcomitans; cardiovascular disease; coronary artery disease; gingival crevicular fluids; hypochlorous acid; lipopolysaccharide; matrix metalloproteinases; myeloperoxidase; neutrophils; oral infections; periodontal diseases; Porphyromonas gingivalis; tissue inhibitor of matrix metalloproteinases

Indexed keywords

CHEMOKINE; CYTOKINE; DOXYCYCLINE; GELATINASE B; LEUKOCYTE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CHRONIC PERIODONTITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; NEUTROPHIL; NONHUMAN; PROTEIN DEGRADATION; UPREGULATION; ADULT; ANIMAL; CHRONIC DISEASE; COMPLICATION; CORONARY DISEASE; IMMUNOLOGY; INFECTION; LEUKOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; RISK;

ADULT; ANIMALS; CHRONIC DISEASE; CHRONIC PERIODONTITIS; CORONARY DISEASE; HUMANS; INFECTION; MATRIX METALLOPROTEINASES; NEUTROPHIL ACTIVATION; NEUTROPHILS; PROTEOLYSIS; RISK;

EID: 84949678824     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425915617521     Document Type: Article

References (259)

1. Kantarci A, Oyaizu K, Van Dyke TE,. Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003; 74: 66-75.
2. Scott DA, Krauss J,. Neutrophils in periodontal inflammation. Front Oral Biol 2012; 15: 56-83.
3. Tonetti MS, Imboden MA, Lang NP,. Neutrophil migration into the gingival sulcus is associated with transepithelial gradients of interleukin-8 and ICAM-1. J Periodontol 1998; 69: 1139-1147.
4. Mealey BL, Rethman MP,. Periodontal disease and diabetes mellitus. Bidirectional relationship. Dent Today 2003; 22: 107-113.
5. Pihlstrom BL, Michalowicz BS, Johnson NW,. Periodontal diseases. Lancet 2005; 366: 1809-1820.
6. Tamaki N, Tomofuji T, Ekuni D, et al. Short-term effects of non-surgical periodontal treatment on plasma level of reactive oxygen metabolites in patients with chronic periodontitis. J Periodontol 2009; 80: 901-906.
7. Desvarieux M, Demmer RT, Rundek T, et al. Periodontal microbiota and carotid intima-media thickness: the Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005; 111: 576-582.
8. Socransky SS, Haffajee AD, Cugini MA, et al. Microbial complexes in subgingival plaque. J Clin Periodontol 1998; 25: 134-144.
9. Kumar PS, Griffen AL, Barton JA, et al. New bacterial species associated with chronic periodontitis. J Dent Res 2003; 82: 338-344.
10. Wade WG,. The oral microbiome in health and disease. Pharmacol Res 2013; 69: 137-143.
11. Erridge C,. Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis 2011; 216: 1-6.
12. Forner L, Larsen T, Kilian M, et al. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol 2006; 33: 401-407.
13. Pussinen PJ, Vilkuna-Rautiainen T, Alfthan G, et al. Severe periodontitis enhances macrophage activation via increased serum lipopolysaccharide. Arterioscler Thromb Vasc Biol 2004; 24: 2174-2180.
14. Geerts SO, Nys M, De MP, et al. Systemic release of endotoxins induced by gentle mastication: association with periodontitis severity. J Periodontol 2002; 73: 73-78.
15. Levels JH, Abraham PR, van den Ende A, et al. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001; 69: 2821-2828.
16. Kallio KA, Buhlin K, Jauhiainen M, et al. Lipopolysaccharide associates with pro-atherogenic lipoproteins in periodontitis patients. Innate Immun 2008; 14: 247-253.
17. Tuomainen AM, Jauhiainen M, Kovanen PT, et al. Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb Pathog 2008; 44: 111-117.
18. Kallio KAE, Hyvärinen K, Kovanen PT, et al. Very low density lipoproteins derived from periodontitis patients facilitate macrophage activation via lipopolysaccharide function. Metabolism 2013; 62: 661-668.
19. Kallio KA, Hätonen KA, Lehto M, et al. Endotoxemia, nutrition, and cardiometabolic disorders. Acta Diabetol 2015; 52: 395-404.
20. Lassenius MI, Pietiläinen KH, Kaartinen K, et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34: 1809-1815.
21. Neves AL, Coelho J, Couto L, et al. Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk. J Mol Endocrinol 2013; 51: R51-R64.
22. Nymark M, Pussinen PJ, Tuomainen AM, et al. Serum lipopolysaccharide activity is associated with the progression of kidney disease in finnish patients with type 1 diabetes. Diabetes Care 2009; 32: 1689-1693.
23. Pussinen PJ, Havulinna AS, Lehto M, et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34: 392-397.
24. Pussinen PJ, Tuomisto K, Jousilahti P, et al. Endotoxemia, immune response to periodontal pathogens, and systemic inflammation associate with incident cardiovascular disease events. Arterioscler Thromb Vasc Biol 2007; 27: 1433-1439.
25. Libby P, Ridker PM, Maseri A,. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
26. Ross R,. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-S420.
27. Epstein SE,. The multiple mechanisms by which infection may contribute to atherosclerosis development and course. Circ Res 2002; 90: 2-4.
28. Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-2138.
29. Kozarov EV, Dorn BR, Shelburne CE, et al. Human atherosclerotic plaque contains viable invasive Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis. Arterioscler Thromb Vasc Biol 2005; 25: e17-e18.
30. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and acute myocardial infarction. BMJ 1989; 298: 779-781.
31. Aas JA, Paster BJ, Stokes LN, et al. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005; 43: 5721-5732.
32. Bahekar AA, Singh S, Saha S, et al. The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: a meta-analysis. Am Heart J 2007; 154: 830-837.
33. Humphrey LL, Fu R, Buckley DI, et al. Periodontal disease and coronary heart disease incidence: a systematic review and meta-analysis. J Gen Intern Med 2008; 23: 2079-2086.
34. Janket SJ, Baird AE, Chuang SK, et al. Meta-analysis of periodontal disease and risk of coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 559-569.
35. Khader YS, Albashaireh ZS, Alomari MA,. Periodontal diseases and the risk of coronary heart and cerebrovascular diseases: a meta-analysis. J Periodontol 2004; 75: 1046-1053.
36. Linden GJ, Herzberg MC, Working group 4 of joint EFP/AAP workshop,. Periodontitis and systemic diseases: a record of discussions of working group 4 of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol 2013; 40 (Suppl. 14): S20-S23.
37. Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association?: a scientific statement from the American Heart Association. Circulation 2012; 125: 2520-2544.
38. Mustapha IZ, Debrey S, Oladubu M, et al. Markers of systemic bacterial exposure in periodontal disease and cardiovascular disease risk: a systematic review and meta-analysis. J Periodontol 2007; 78: 2289-2302.
39. Scannapieco FA, Bush RB, Paju S,. Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol 2003; 8: 38-53.
40. Alfakry H, Paju S, Sinisalo J, et al. Periodontopathogen- and host-derived immune response in acute coronary syndrome. Scand J Immunol 2011; 74: 383-389.
41. Fredriksson MI, Figueredo CM, Gustafsson A, et al. Effect of periodontitis and smoking on blood leukocytes and acute-phase proteins. J Periodontol 1999; 70: 1355-1360.
42. Garcia RA, Pantazatos DP, Gessner CR, et al. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol 2005; 67: 1128-1136.
43. Teles R, Wang CY,. Mechanisms involved in the association between periodontal diseases and cardiovascular disease. Oral Dis 2011; 17: 450-461.
44. Turunen SP, Kummu O, Harila K, et al. Recognition of Porphyromonas gingivalis gingipain epitopes by natural IgM binding to malondialdehyde modified low-density lipoprotein. PLoS One 2012; 7: e34910-e34910.
45. Buhlin K, Hultin M, Norderyd O, et al. Periodontal treatment influences risk markers for atherosclerosis in patients with severe periodontitis. Atherosclerosis 2009; 206: 518-522.
46. D'Aiuto F, Orlandi M, Gunsolley JC,. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Periodontol 2013; 84: S85-S105.
47. Teeuw WJ, Slot DE, Susanto H, et al. Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. J Clin Periodontol 2014; 41: 70-79.
48. Olsen I,. Update on bacteraemia related to dental procedures. Transfus Apher Sci 2008; 39: 173-178.
49. Kinane DF, Riggio MP, Walker KF, et al. Bacteraemia following periodontal procedures. J Clin Periodontol 2005; 32: 708-713.
50. Horliana AC, Chambrone L, Foz AM, et al. Dissemination of periodontal pathogens in the bloodstream after periodontal procedures: a systematic review. PLoS One 2014; 9: e98271-e98271.
51. Rafferty B, Jonsson D, Kalachikov S, et al. Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions. J Intern Med 2011; 270: 273-280.
52. Haraszthy VI, Zambon JJ, Trevisan M, et al. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000; 71: 1554-1560.
53. Kozarov E,. Bacterial invasion of vascular cell types: vascular infectology and atherogenesis. Future Cardiol 2012; 8: 123-138.
54. Reyes L, Herrera D, Kozarov E, et al. Periodontal bacterial invasion and infection: contribution to atherosclerotic pathology. J Clin Periodontol 2013; 40 (Suppl. 14): S30-S50.
55. Loos BG, Craandijk J, Hoek FJ, et al. Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 2000; 71: 1528-1534.
56. Noack B, Genco RJ, Trevisan M, et al. Periodontal infections contribute to elevated systemic C-reactive protein level. J Periodontol 2001; 72: 1221-1227.
57. Pussinen PJ, Paju S, Mäntyla P, et al. Serum microbial- and host-derived markers of periodontal diseases: a review. Curr Med Chem 2007; 14: 2402-2412.
58. Schenkein HA, Loos BG,. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J Clin Periodontol 2013; 40 (Suppl. 14): S51-S69.
59. Leishman SJ, Do HL, Ford PJ,. Cardiovascular disease and the role of oral bacteria. J Oral Microbiol 2010; 2: 1-13.
60. Pussinen PJ, Jauhiainen M, Vilkuna-Rautiainen T, et al. Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J Lipid Res 2004; 45: 139-147.
61. Pattison DI, Davies MJ,. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 2006; 13: 3271-3290.
62. Daugherty A, Dunn JL, Rateri DL, et al. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94: 437-444.
63. Malle E, Wag G, Thiery J, et al. Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 2001; 289: 894-900.
64. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000; 267: 4495-4503.
65. Malle E, Woenckhaus C, Waeg G, et al. Immunological evidence for hypochlorite-modified proteins in human kidney. Am J Pathol 1997; 150: 603-615.
66. Grone HJ, Grone EF, Malle E,. Immunohistochemical detection of hypochlorite-modified proteins in glomeruli of human membranous glomerulonephritis. Lab Invest 2002; 82: 5-14.
67. Malle E, Buch T, Grone HJ,. Myeloperoxidase in kidney disease. Kidney Int 2003; 64: 1956-1967.
68. Nagase H, Visse R, Murphy G,. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
69. Sorsa T, Tjäderhane L, Konttinen YT, et al. Matrix metalloproteinases: contribution to pathogenesis, diagnosis and treatment of periodontal inflammation. Ann Med 2006; 38: 306-321.
70. Sorsa T, Tjäderhane L, Salo T,. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004; 10: 311-318.
71. Visse R, Nagase H,. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-839.
72. Nissinen L, Kahari VM,. Matrix metalloproteinases in inflammation. Biochim Biophys Acta 2014; 1840: 2571-2580.
73. Hanemaaijer R, Sorsa T, Konttinen YT, et al. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells. Regulation by tumor necrosis factor-alpha and doxycycline. J Biol Chem 1997; 272: 31504-31509.
74. Prikk K, Maisi P, Pirilä E, et al. In vivo collagenase-2 (MMP-8) expression by human bronchial epithelial cells and monocytes/macrophages in bronchiectasis. J Pathol 2001; 194: 232-238.
75. Wahlgren J, Maisi P, Sorsa T, et al. Expression and induction of collagenases (MMP-8 and -13) in plasma cells associated with bone-destructive lesions. J Pathol 2001; 194: 217-224.
76. Weiss SJ,. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-376.
77. Ala-aho R, Kahari VM,. Collagenases in cancer. Biochimie 2005; 87: 273-286.
78. Hasty KA, Jeffrey JJ, Hibbs MS, et al. The collagen substrate specificity of human neutrophil collagenase. J Biol Chem 1987; 262: 10048-10052.
79. Owen CA, Campbell EJ,. The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 1999; 65: 137-150.
80. Safkan-Seppalä B, Sorsa T, Tervahartiala T, et al. Collagenases in gingival crevicular fluid in type 1 diabetes mellitus. J Periodontol 2006; 77: 189-194.
81. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001; 104: 1899-1904.
82. Salminen A, Åstrom P, Metso J, et al. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity. FASEB J 2015; 29: 1435-1445.
83. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation 2004; 110: 337-343.
84. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37: 235-239.
85. Sorsa T, Tervahartiala T, Leppilahti J, et al. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res 2011; 63: 108-113.
86. van den Borne SW, Cleutjens JP, Hanemaaijer R, et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009; 18: 37-43.
87. Galis ZS, Muszynski M, Sukhova GK, et al. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501-507.
88. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
89. Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis 2006; 187: 161-169.
90. Momiyama Y, Ohmori R, Tanaka N, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis 2010; 209: 206-210.
91. Kato R, Momiyama Y, Ohmori R, et al. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J 2005; 69: 1035-1040.
92. Qiang H, Zhou ZX, Ma AQ, et al. [Implications of serum matrix metalloproteinase-8 elevation in patients with acute coronary syndrome]. Nan Fang Yi Ke Da Xue Xue Bao 2007; 27: 831-833.
93. Pussinen PJ, Sarna S, Puolakkainen M, et al. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence. Int J Cardiol 2013; 167: 362-368.
94. Tuomainen AM, Kormi I, Havulinna AS, et al. Serum tissue-degrading proteinases and incident cardiovascular disease events. Eur J Prev Cardiol 2014; 21: 806-812.
95. Tuomainen AM, Nyyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol 2007; 27: 2722-2728.
96. Hastbacka J, Tiainen M, Hynninen M, et al. Serum matrix metalloproteinases in patients resuscitated from cardiac arrest. The association with therapeutic hypothermia. Resuscitation 2012; 83: 197-201.
97. Holopainen JM, Moilanen JA, Sorsa T, et al. Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Invest Ophthalmol Vis Sci 2003; 44: 2550-2556.
98. Saari H, Suomalainen K, Lindy O, et al. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Commun 1990; 171: 979-987.
99. Sorsa T, Ingman T, Suomalainen K, et al. Identification of proteases from periodontopathogenic bacteria as activators of latent human neutrophil and fibroblast-type interstitial collagenases. Infect Immun 1992; 60: 4491-4495.
100. Palm F, Lahdentausta L, Sorsa T, et al. Biomarkers of periodontitis and inflammation in ischemic stroke: A case-control study. Innate Immun 2014; 20: 511-518.
101. Hernandez M, Gamonal J, Tervahartiala T, et al. Associations between matrix metalloproteinase-8 and -14 and myeloperoxidase in gingival crevicular fluid from subjects with progressive chronic periodontitis: a longitudinal study. J Periodontol 2010; 81: 1644-1652.
102. Leppilahti JM, Kallio MA, Tervahartiala T, et al. Gingival crevicular fluid matrix metalloproteinase-8 levels predict treatment outcome among smokers with chronic periodontitis. J Periodontol 2014; 85: 250-260.
103. Mäntyla P, Stenman M, Kinane D, et al. Monitoring periodontal disease status in smokers and nonsmokers using a gingival crevicular fluid matrix metalloproteinase-8-specific chair-side test. J Periodontal Res 2006; 41: 503-512.
104. Mäntyla P, Stenman M, Kinane DF, et al. Gingival crevicular fluid collagenase-2 (MMP-8) test stick for chair-side monitoring of periodontitis. J Periodontal Res 2003; 38: 436-439.
105. Marcaccini AM, Meschiari CA, Zuardi LR, et al. Gingival crevicular fluid levels of MMP-8, MMP-9, TIMP-2, and MPO decrease after periodontal therapy. J Clin Periodontol 2010; 37: 180-190.
106. Marcaccini AM, Novaes AB Jr, Meschiari CA, et al. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy. Clin Chim Acta 2009; 409: 117-122.
107. Merchant AT, Pitiphat W, Parker J, et al. Can nonstandardized bitewing radiographs be used to assess the presence of alveolar bone loss in epidemiologic studies? Community Dent Oral Epidemiol 2004; 32: 271-276.
108. Sorsa M, Hameila M, Järviluoma E,. Handling anticancer drugs: from hazard identification to risk management? Ann N Y Acad Sci 2006; 1076: 628-634.
109. Sorsa T, Hernandez M, Leppilahti J, et al. Detection of gingival crevicular fluid MMP-8 levels with different laboratory and chair-side methods. Oral Dis 2010; 16: 39-45.
110. Golub LM, Lee HM, Stoner JA, et al. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol 2008; 79: 1409-1418.
111. Kivelä-Rajamaki M, Maisi P, Srinivas R, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res 2003; 38: 583-590.
112. Hernandez M, Gamonal J, Salo T, et al. Reduced expression of lipopolysaccharide-induced CXC chemokine in Porphyromonas gingivalis-induced experimental periodontitis in matrix metalloproteinase-8 null mice. J Periodontal Res 2011; 46: 58-66.
113. Kuula H, Salo T, Pirilä E, et al. Local and systemic responses in matrix metalloproteinase 8-deficient mice during Porphyromonas gingivalis -induced periodontitis. Infect Immun 2009; 77: 850-859.
114. Sternlicht MD, Werb Z,. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
115. Lijnen HR, Collen D,. Matrix metalloproteinase system deficiencies and matrix degradation. Thromb Haemost 1999; 82: 837-845.
116. Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992; 89: 1478-1484.
117. Okada Y, Gonoji Y, Naka K, et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992; 267: 21712-21719.
118. Nguyen M, Arkell J, Jackson CJ,. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001; 33: 960-970.
119. Opdenakker G, Van den Steen PE, Van Damme J,. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001; 22: 571-579.
120. Stahle-Backdahl M, Parks WC,. 92-kd gelatinase is actively expressed by eosinophils and stored by neutrophils in squamous cell carcinoma. Am J Pathol 1993; 142: 995-1000.
121. Tetlow LC, Adlam DJ, Woolley DE,. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001; 44: 585-594.
122. Van den Steen PE, Dubois B, Nelissen I, et al. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37: 375-536.
123. Birkedal-Hansen H,. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993; 64: 474-484.
124. Elkington PT, O'Kane CM, Friedland JS,. The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol 2005; 142: 12-20.
125. Westerlund U, Ingman T, Lukinmaa PL, et al. Human neutrophil gelatinase and associated lipocalin in adult and localized juvenile periodontitis. J Dent Res 1996; 75: 1553-1563.
126. Wilhelm SM, Collier IE, Marmer BL, et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989; 264: 17213-17221.
127. Fosang AJ, Neame PJ, Last K, et al. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992; 267: 19470-19474.
128. Senior RM, Griffin GL, Fliszar CJ, et al. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991; 266: 7870-7875.
129. Backstrom JR, Tokes ZA,. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem 1995; 64: 1312-1318.
130. Ito A, Mukaiyama A, Itoh Y, et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996; 271: 14657-14660.
131. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-2131.
132. Cho A, Reidy MA,. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002; 91: 845-851.
133. Gu Y, Lee HM, Sorsa T, et al. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: a mechanistic link between local and systemic inflammation. Pharmacol Res 2011; 64: 573-579.
134. Lalla E, Lamster IB, Hofmann MA, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2003; 23: 1405-1411.
135. Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31: 40-47.
136. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003; 51: 295-300.
137. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211-217.
138. Renko J, Kalela A, Jaakkola O, et al. Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest 2004; 64: 255-261.
139. Brown DL, Desai KK, Vakili BA, et al. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24: 733-738.
140. Burke B,. The role of matrix metalloproteinase 7 in innate immunity. Immunobiology 2004; 209: 51-56.
141. de Coignac AB, Elson G, Delneste Y, et al. Cloning of MMP-26. A novel matrilysin-like proteinase. Eur J Biochem 2000; 267: 3323-3329.
142. Wielockx B, Libert C, Wilson C,. Matrilysin (matrix metalloproteinase-7): a new promising drug target in cancer and inflammation? Cytokine Growth Factor Rev 2004; 15: 111-115.
143. Wilson CL, Matrisian LM,. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996; 28: 123-136.
144. Nagase H, Woessner JF Jr,. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494.
145. Emingil G, Tervahartiala T, Mantyla P, et al. Gingival crevicular fluid matrix metalloproteinase (MMP)-7, extracellular MMP inducer, and tissue inhibitor of MMP-1 levels in periodontal disease. J Periodontol 2006; 77: 2040-2050.
146. Uitto VJ, Overall CM, McCulloch C,. Proteolytic host cell enzymes in gingival crevice fluid. Periodontol 2000 2003; 31: 77-104.
147. Uitto VJ, Salonen JI, Firth JD, et al. Matrilysin (matrix metalloproteinase-7) expression in human junctional epithelium. J Dent Res 2002; 81: 241-246.
148. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A 1996; 93: 9748-9753.
149. Nilsson L, Jonasson L, Nijm J, et al. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clin Chem 2006; 52: 1522-1527.
150. Dozier S, Escobar GP, Lindsey ML,. Matrix metalloproteinase (MMP)-7 activates MMP-8 but not MMP-13. Med Chem 2006; 2: 523-526.
151. Tervahartiala T, Pirilä E, Ceponis A, et al. The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. J Dent Res 2000; 79: 1969-1977.
152. Beaudeux JL, Giral P, Bruckert E, et al. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42: 121-131.
153. Brew K, Dinakarpandian D, Nagase H,. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267-283.
154. Stetler-Stevenson WG,. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008; 1: re6-re6.
155. Dollery CM, McEwan JR, Henney AM,. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-868.
156. Welgus HG, Campbell EJ, Bar-Shavit Z, et al. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J Clin Invest 1985; 76: 219-224.
157. Cavusoglu E, Ruwende C, Chopra V, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. Am Heart J 2006; 151: 1101 e1101-e1108.
158. Lubos E, Schnabel R, Rupprecht HJ, et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. Eur Heart J 2006; 27: 150-156.
159. Naesse EP, Schreurs O, Helgeland K, et al. Matrix metalloproteinases and their inhibitors in gingival mast cells in persons with and without human immunodeficiency virus infection. J Periodontal Res 2003; 38: 575-582.
160. Gursoy UK, Könönen E, Pradhan-Palikhe P, et al. Salivary MMP-8, TIMP-1, and ICTP as markers of advanced periodontitis. J Clin Periodontol 2010; 37: 487-493.
161. Ingman T, Tervahartiala T, Ding Y, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol 1996; 23: 1127-1132.
162. Payne JB, Golub LM, Stoner JA, et al. The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc 2011; 142: 262-273.
163. Belaaouaj A, Kim KS, Shapiro SD,. Degradation of outer membrane protein A in Escherichia coli killing by neutrophil elastase. Science 2000; 289: 1185-1188.
164. Hiemstra PS, van Wetering S, Stolk J,. Neutrophil serine proteinases and defensins in chronic obstructive pulmonary disease: effects on pulmonary epithelium. Eur Respir J 1998; 12: 1200-1208.
165. Ferry G, Lonchampt M, Pennel L, et al. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 1997; 402: 111-115.
166. Okada Y, Nakanishi I,. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 ('gelatinase') by human neutrophil elastase and cathepsin G. FEBS Lett 1989; 249: 353-356.
167. Henriksen PA, Sallenave JM,. Human neutrophil elastase: mediator and therapeutic target in atherosclerosis. Int J Biochem Cell Biol 2008; 40: 1095-1100.
168. Dollery CM, Owen CA, Sukhova GK, et al. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation 2003; 107: 2829-2836.
169. Smith FB, Fowkes FG, Rumley A, et al. Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study. Eur Heart J 2000; 21: 1607-1613.
170. Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J Leukoc Biol 2007; 82: 1420-1429.
171. Ujiie Y, Oida S, Gomi K, et al. Neutrophil elastase is involved in the initial destruction of human periodontal ligament. J Periodontal Res 2007; 42: 325-330.
172. Wohlfeil M, Scharf S, Siegelin Y, et al. Increased systemic elastase and C-reactive protein in aggressive periodontitis (CLOI-D-00160R2). Clin Oral Investig 2012; 16: 1199-1207.
173. Eickholz P, Siegelin Y, Scharf S, et al. Non-surgical periodontal therapy decreases serum elastase levels in aggressive but not in chronic periodontitis. J Clin Periodontol 2013; 40: 327-333.
174. Anatoliotakis N, Deftereos S, Bouras G, et al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Curr Top Med Chem 2013; 13: 115-138.
175. Nicholls SJ, Hazen SL,. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1102-1111.
176. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
177. Heslop CL, Frohlich JJ, Hill JS,. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography. J Am Coll Cardiol 2010; 55: 1102-1109.
178. Scharnagl H, Kleber ME, Genser B, et al. Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography-the LURIC study. Int J Cardiol 2014; 174: 96-105.
179. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136-2142.
180. Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879-891.
181. Nauseef WM,. Myeloperoxidase in human neutrophil host defence. Cell Microbiol 2014; 16: 1146-1155.
182. Malle E, Marsche G, Panzenboeck U, et al. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 2006; 445: 245-255.
183. Hazell LJ, Arnold L, Flowers D, et al. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996; 97: 1535-1544.
184. Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001; 276: 41279-41287.
185. Peppin GJ, Weiss SJ,. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci U S A 1986; 83: 4322-4326.
186. Weiss SJ, Peppin G, Ortiz X, et al. Oxidative autoactivation of latent collagenase by human neutrophils. Science 1985; 227: 747-749.
187. Michaelis J, Vissers MC, Winterbourn CC,. Different effects of hypochlorous acid on human neutrophil metalloproteinases: activation of collagenase and inactivation of collagenase and gelatinase. Arch Biochem Biophys 1992; 292: 555-562.
188. Fu X, Kassim SY, Parks WC, et al. Hypochlorous acid generated by myeloperoxidase modifies adjacent tryptophan and glycine residues in the catalytic domain of matrix metalloproteinase-7 (matrilysin): an oxidative mechanism for restraining proteolytic activity during inflammation. J Biol Chem 2003; 278: 28403-28409.
189. Shabani F, McNeil J, Tippett L,. The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radic Res 1998; 28: 115-123.
190. Wang Y, Rosen H, Madtes DK, et al. Myeloperoxidase inactivates TIMP-1 by oxidizing its N-terminal cysteine residue: an oxidative mechanism for regulating proteolysis during inflammation. J Biol Chem 2007; 282: 31826-31834.
191. Buchmann R, Hasilik A, Van Dyke TE, et al. Amplified crevicular leukocyte activity in aggressive periodontal disease. J Dent Res 2002; 81: 716-721.
192. Cifcibasi E, Koyuncuoglu C, Ciblak M, et al. Evaluation of local and systemic levels of interleukin-17, interleukin-23, and myeloperoxidase in response to periodontal therapy in patients with generalized aggressive periodontitis. Inflammation 2015; 38: 1959-1968.
193. Durrani F, Singh R,. Myeloperoxidase level around dental implants as an indicator of an inflammatory process. Indian J Dent 2015; 6: 2-6.
194. Over C, Yamalik N, Yavuzyilmaz E, et al. Myeloperoxidase activity in peripheral blood, neutrophil crevicular fluid and whole saliva of patients with periodontal disease. J Nihon Univ Sch Dent 1993; 35: 235-240.
195. Kaner D, Bernimoulin JP, Kleber BM, et al. Gingival crevicular fluid levels of calprotectin and myeloperoxidase during therapy for generalized aggressive periodontitis. J Periodontal Res 2006; 41: 132-139.
196. Leppilahti JM, Hernandez-Rios PA, Gamonal JA, et al. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnostic value for chronic periodontitis. J Clin Periodontol 2014; 41: 348-356.
197. Smith QT, Hinrichs JE, Melnyk RS,. Gingival crevicular fluid myeloperoxidase at periodontitis sites. J Periodontal Res 1986; 21: 45-55.
198. Wei PF, Ho KY, Ho YP, et al. The investigation of glutathione peroxidase, lactoferrin, myeloperoxidase and interleukin-1beta in gingival crevicular fluid: implications for oxidative stress in human periodontal diseases. J Periodontal Res 2004; 39: 287-293.
199. Yamalik N, Caglayan F, Kilinc K, et al. The importance of data presentation regarding gingival crevicular fluid myeloperoxidase and elastase-like activity in periodontal disease and health status. J Periodontol 2000; 71: 460-467.
200. Marcaccini AM, Amato PA, Leao FV, et al. Myeloperoxidase activity is increased in gingival crevicular fluid and whole saliva after fixed orthodontic appliance activation. Am J Orthod Dentofacial Orthop 2010; 138: 613-616.
201. Meschiari CA, Marcaccini AM, Santos Moura BC, et al. Salivary MMPs, TIMPs, and MPO levels in periodontal disease patients and controls. Clin Chim Acta 2013; 421: 140-146.
202. Nizam N, Gumus P, Pitkanen J, et al. Serum and salivary matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or aggressive periodontitis. Inflammation 2014; 37: 1771-1778.
203. Accorsi-Mendonca T, Silva EJ, Marcaccini AM, et al. Evaluation of gelatinases, tissue inhibitor of matrix metalloproteinase-2, and myeloperoxidase protein in healthy and inflamed human dental pulp tissue. J Endod 2013; 39: 879-882.
204. Miyasaki KT, Nemirovskiy E,. Myeloperoxidase isoform activities released by human neutrophils in response to dental and periodontal bacteria. Oral Microbiol Immunol 1997; 12: 27-32.
205. Liskmann S, Vihalemm T, Salum O, et al. Characterization of the antioxidant profile of human saliva in peri-implant health and disease. Clin Oral Implants Res 2007; 18: 27-33.
206. Sanchez-Siles M, Lucas-Azorin J, Salazar-Sanchez N, et al. Salivary concentration of oxidative stress biomarkers in a group of patients with peri-implantitis: a transversal study. Clin Implant Dent Relat Res. Epub ahead of print 31 Jul 2015. DOI: 10.1111/cid.12367.
207. Liskmann S, Zilmer M, Vihalemm T, et al. Correlation of peri-implant health and myeloperoxidase levels: a cross-sectional clinical study. Clin Oral Implants Res 2004; 15: 546-552.
208. Malik N, Naik D, Uppoor A,. Levels of myeloperoxidase and alkaline phosphatase in periimplant sulcus fluid in health and disease and after nonsurgical therapy. Implant Dent 2015; 24: 434-440.
209. Klebanoff SJ, Kettle AJ, Rosen H, et al. Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol 2013; 93: 185-198.
210. Kaplan MJ, Radic M,. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012; 189: 2689-2695.
211. Cooper PR, Palmer LJ, Chapple IL,. Neutrophil extracellular traps as a new paradigm in innate immunity: friend or foe? Periodontol 2000 2013; 63: 165-197.
212. Hirschfeld J, Dommisch H, Skora P, et al. Neutrophil extracellular trap formation in supragingival biofilms. Int J Med Microbiol 2015; 305: 453-463.
213. Mohanty T, Sjögren J, Kahn F, et al. A novel mechanism for NETosis provides antimicrobial defense at the oral mucosa. Blood 2015; 126: 2128-2137.
214. Borissoff JI, Joosen IA, Versteylen MO, et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 2013; 33: 2032-2040.
215. Range H, Labreuche J, Louedec L, et al. Periodontal bacteria in human carotid atherothrombosis as a potential trigger for neutrophil activation. Atherosclerosis 2014; 236: 448-455.
216. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296: 2391-2394.
217. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110: 1134-1139.
218. Debabrata K, Prasanta B, Vineet N, et al. Aggressive periodontitis: an appraisal of systemic effects on its etiology-genetic aspect. J Indian Soc Periodontol 2015; 19: 169-173.
219. Erciyas K, Pehlivan S, Sever T, et al. Genetic variation of myeloperoxidase gene contributes to aggressive periodontitis: a preliminary association study in Turkish population. Dis Markers 2010; 28: 95-99.
220. Meisel P, Krause T, Cascorbi I, et al. Gender and smoking-related risk reduction of periodontal disease with variant myeloperoxidase alleles. Genes Immun 2002; 3: 102-106.
221. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106: 2894-2900.
222. Ionita MG, van den Borne P, Catanzariti LM, et al. High neutrophil numbers in human carotid atherosclerotic plaques are associated with characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2010; 30: 1842-1848.
223. Marfil-Alvarez R, Mesa F, Arrebola-Moreno A, et al. Acute myocardial infarct size is related to periodontitis extent and severity. J Dent Res 2014; 93: 993-998.
224. Mayadas TN, Cullere X, Lowell CA,. The multifaceted functions of neutrophils. Annu Rev Pathol 2014; 9: 181-218.
225. Bartold PM,. Periodontal tissues in health and disease: introduction. Periodontol 2000 2006; 40: 7-10.
226. Nanci A, Bosshardt DD,. Structure of periodontal tissues in health and disease. Periodontol 2000 2006; 40: 11-28.
227. Lusis AJ,. Atherosclerosis. Nature 2000; 407: 233-241.
228. Jones CB, Sane DC, Herrington DM,. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823.
229. Lauhio A, Konttinen YT, Tschesche H, et al. Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis. Antimicrob Agents Chemother 1994; 38: 400-402.
230. Lauhio A, Salo T, Ding Y, et al. In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol 1994; 98: 21-28.
231. Salminen A, Pussinen PJ, Payne JB, et al. Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflamm Res 2013; 62: 711-720.
232. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12-26.
233. Akahane T, Akahane M, Shah A, et al. TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 2004; 324: 440-445.
234. Kormi I, Alfakry H, Tervahartiala T, et al. The effect of prolonged systemic doxycycline therapy on serum tissue degrading proteinases in coronary bypass patients: a randomized, double-masked, placebo-controlled clinical trial. Inflamm Res 2014; 63: 329-334.
235. Lauhio A, Hästbacka J, Pettila V, et al. Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 2011; 64: 590-594.
236. Reinhardt RA, Stoner JA, Golub LM, et al. Association of gingival crevicular fluid biomarkers during periodontal maintenance with subsequent progressive periodontitis. J Periodontol 2010; 81: 251-259.
237. Frankwich K, Tibble C, Torres-Gonzalez M, et al. Proof of concept: matrix metalloproteinase inhibitor decreases inflammation and improves muscle insulin sensitivity in people with type 2 diabetes. J Inflamm (Lond) 2012; 9: 35-35.
238. DeLano FA, Schmid-Schonbein GW,. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension 2008; 52: 415-423.
239. Smith K, Leyden JJ,. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005; 27: 1329-1342.
240. Akman S, Canakci V, Kara A, et al. Therapeutic effects of alpha lipoic acid and vitamin C on alveolar bone resorption after experimental periodontitis in rats: a biochemical, histochemical, and stereologic study. J Periodontol 2013; 84: 666-674.
241. Gomes DA, Pires JR, Zuza EP, et al. Myeloperoxidase as inflammatory marker of periodontal disease: experimental study in rats. Immunol Invest 2009; 38: 117-122.
242. Spolidorio LC, Lucas PD, Steffens JP, et al. Influence of parstatin on experimental periodontal disease and repair in rats. J Periodontol 2014; 85: 1266-1274.
243. Araujo AA, Lopes de Souza G, Souza TO, et al. Olmesartan decreases IL-1beta and TNF-alpha levels; downregulates MMP-2, MMP-9, COX-2, and RANKL; and upregulates OPG in experimental periodontitis. Naunyn Schmiedebergs Arch Pharmacol 2013; 386: 875-884.
244. Araujo AA, Varela H, Brito GA, et al. Azilsartan increases levels of IL-10, down-regulates MMP-2, MMP-9, RANKL/RANK, Cathepsin K and up-regulates OPG in an experimental periodontitis model. PLoS One 2014; 9: e96750-e96750.
245. de Araujo Junior RF, Souza TO, de Medeiros CA, et al. Carvedilol decrease IL-1beta and TNF-alpha, inhibits MMP-2, MMP-9, COX-2, and RANKL expression, and up-regulates OPG in a rat model of periodontitis. PLoS One 2013; 8: e66391-e66391.
246. de Araujo Junior RF, Souza TO, de Moura LM, et al. Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis. PLoS One 2013; 8: e75322-e75322.
247. Holzhausen M, Balejo RD, Lara GM, et al. Nafamostat mesilate, a potent tryptase inhibitor, modulates periodontitis in rats. Clin Oral Investig 2011; 15: 967-973.
248. Goes P, Melo IM, Silva LM, et al. Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats. J Periodontal Res 2014; 49: 45-54.
249. Kumar AP, Reynolds WF,. Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 2005; 331: 442-451.
250. Dalcico R, de Menezes AM, Deocleciano OB, et al. Protective mechanisms of simvastatin in experimental periodontal disease. J Periodontol 2013; 84: 1145-1157.
251. Kadoglou NP, Sailer N, Fotiadis G, et al. The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8. Exp Clin Endocrinol Diabetes 2014; 122: 44-49.
252. Malle E, Furtmuller PG, Sattler W, et al. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007; 152: 838-854.
253. McCarty MF,. Supplementary taurine may stabilize atheromatous plaque by antagonizing the activation of metalloproteinases by hypochlorous acid. Med Hypotheses 2004; 63: 414-418.
254. Rathnayake N, Gustafsson A, Norhammar A, et al. Salivary matrix metalloproteinase-8 and -9 and myeloperoxidase in relation to coronary heart and periodontal diseases: a subgroup report from the PAROKRANK study (periodontitis and its relation to coronary artery disease). PLoS One 2015; 10: e0126370-e0126370.
255. Li L, Messas E, Batista EL Jr, et al. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002; 105: 861-867.
256. Liu C, Xie G, Huang W, et al. Elevated serum myeloperoxidase activities are significantly associated with the prevalence of ACS and High LDL-C levels in CHD patients. J Atheroscler Thromb 2012; 19: 435-443.
257. Spallarossa P, Garibaldi S, Barisione C, et al. Postprandial serum induces apoptosis in endothelial cells: Role of polymorphonuclear-derived myeloperoxidase and metalloproteinase-9 activity. Atherosclerosis 2008; 198: 458-467.
258. Alfakry H, Sinisalo J, Paju S, et al. The association of serum neutrophil markers and acute coronary syndrome. Scand J Immunol 2012; 76: 181-187.
259. D'Aiuto F, Nibali L, Parkar M, et al. Oxidative stress, systemic inflammation, and severe periodontitis. J Dent Res 2010; 89: 1241-1246.